Polymalt

Quick links to important sections

Polymalt

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Polymalt

Polymalt is a compound pharmaceutical preparation classified as a haematinic, which is a medicinal agent used to enhance the blood's capacity, primarily by supporting red blood cell formation. This medication is defined as a combination product designed for the oral route, typically supplied as tablets, capsules, syrup, or drops. Its primary general purpose is correcting and preventing specific nutritional deficiencies that can impair normal blood function.


Quick Facts

Property Description
Active Ingredients Iron(III)-hydroxide polymaltose complex, Cyanocobalamin
Form Tablets, Capsules, Syrup, or Oral Drops
Pharmacological Class Haematinics (Anti-anemic Trivalent Iron Preparation)
Common Use Nutritional deficiency correction for blood formation
Origin Synthetic/Derived macromolecular complex

What Type of Medicine is Polymalt? (Definition and Classification)

Polymalt belongs to the pharmacological class of Haematinics, falling under the Anatomical Therapeutic Chemical (ATC) classification B03AB05 for Trivalent iron preparations. It functions as an oral iron preparation complex, addressing deficiencies that impact the production of healthy red blood cells. Its defining characteristic is the combination of its two primary active constituents, Iron(III)-hydroxide polymaltose complex and Cyanocobalamin, to address multiple facets of deficiency simultaneously. The formulation is often used in cases where patients require both iron and Vitamin B12 replenishment, such as managing anemia linked to nutritional malabsorption.

Polymalt's Unique Composition: Ferric Iron and Vitamin B12

The preparation's efficacy relies on its two active ingredients: Elemental Iron, sourced from the Iron(III)-hydroxide polymaltose complex (IPC), and Cyanocobalamin (Vitamin B12). The IPC is a synthetic/derived macromolecular complex where ferric iron (Fe³⁺) is non-ionically bound to a polymaltose carrier. This specific structure minimizes the release of free iron ions in the gut, which often results in better gastrointestinal tolerance compared to older ferrous iron salts. This specific iron complex is associated with fewer digestive issues. The inclusion of Cyanocobalamin is vital, as this B vitamin is necessary for cell division, DNA synthesis, and maintaining proper nerve function.

General Purpose and Mechanism Principle

Polymalt works by systematically restoring the body's essential reserves of the key micronutrients necessary for effective erythropoiesis (red blood cell production). The iron component directly provides the core material for hemoglobin synthesis and oxygen transport, while the Vitamin B12 component ensures the new red blood cells mature correctly. This controlled delivery system and dual-nutrient approach support vital bodily functions, helping to overcome the fatigue and compromised energy levels often linked to these nutritional deficiencies.

Regulatory References

  1. Iron (MedlinePlus/NIH)

What side effects are possible with Polymalt?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Polymalt (Iron(III)-hydroxide polymaltose complex and Cyanocobalamin), based strictly on government regulatory documentation. The safety profile is structured around the officially classified adverse events and important restrictions on use.


Adverse Reaction Classifications

The most commonly documented adverse reactions involve the Gastrointestinal System. These effects, such as nausea, vomiting, constipation, diarrhoea, and abdominal pain, are typically classified as uncommon or rare in regulatory labeling for the iron complex. A non-pathological effect, the darkening of stools, is an expected finding associated with unabsorbed oral iron content and is consistently noted in official documents.

Serious Reactions and Safety Constraints

The regulatory profile documents the potential for rare severe hypersensitivity or anaphylaxis, a clinically significant event associated with the Cyanocobalamin component. This is classified as a rare or not known frequency event. High-level safety constraints define the groups for whom this medication is contraindicated. This includes individuals with iron overload (such as hemochromatosis), severe hepatic impairment, and anaemias not caused by iron or B12 deficiency (e.g., haemolytic anaemia). The safety profile relies on the ICH/EMA frequency bands to communicate risk likelihood, establishing a clear descriptive framework for its safety characteristics.

Overdose and Emergency Response

Overdose and When to Seek Help

Polymalt is a term used for iron(III)-hydroxide polymaltose complex (IPC), an oral iron supplement. Official regulatory information regarding overdose for this specific complex often contrasts with that for simple ferrous salts due to its controlled release mechanism and stability.

Overdose Aspect Official Regulatory Stance for Polymalt (IPC)
Documented Presentations No toxic reactions or overdose cases have been formally associated with iron(III)-hydroxide polymaltose complex in specific product labeling.
Associated Symptoms None explicitly documented in regulatory overdose sections for IPC. Symptoms described relate to general iron salt overdose, such as nausea, vomiting, abdominal pain, and circulatory collapse, which require immediate medical intervention.
Emergency Action Required Seek immediate medical attention for any suspected overdose of an iron-containing product. Treatment for general iron overdose may involve supportive care, monitoring of serum iron levels, or chelation therapy in severe cases.

It is crucial to recognize that the safety profile of IPC suggests a very low risk of acute poisoning, even at high accidental doses, which distinguishes it from simpler iron compounds. However, due to the inherent toxicity risk of elemental iron, any excessive ingestion, particularly in children, must be treated as a medical emergency. Contact a poison control center or emergency services right away if you suspect a Polymalt overdose, even if the person appears well, as symptoms of severe toxicity can have a delayed onset.

Therapeutic Uses of Polymalt

What Polymalt Treats: Main Uses and Benefits

This combination therapy is commonly used to help with systemic imbalances caused by micronutrient deficits. Polymalt is commonly used to help manage conditions such as Iron Deficiency Anemia (IDA), latent iron deficiency, and specific nutritional deficiencies linked to Vitamin B12 shortage.


Therapeutic Focus and Benefits

This medicine is commonly used to help manage the conditions of IDA and related deficiencies, including cases of latent iron deficiency where stores are low. It is applied in addressing symptom clusters that create noticeable physiological strain, specifically chronic fatigue, generalized physical weakness, and compromised energy levels that are related to systemic imbalance. This supports general well-being during symptomatic periods and contributes to easing the overall symptom load.

The medication is relevant in contexts involving heightened systemic burden, such as during pregnancy and lactation, periods of intensive childhood growth, or following persistent chronic blood loss. It is commonly used when supportive symptom management is appropriate in these high-demand scenarios and may help with avoiding the intensification of nutritional deficits and assists with maintaining functional stability related to nutrient stores.

“This supportive treatment helps patients cope more steadily with symptom fluctuations associated with low iron and Vitamin B12.”


Quick Fact Block

Quick Fact: Addressing Nutritional Deficits Description
Main Therapeutic Goal Managing IDA, latent iron deficiency, and B12-related nutritional shortages.
Symptoms Addressed Chronic fatigue, physical weakness, and compromised energy levels.
Key Patient Scenarios Used during pregnancy, intensive growth, and after chronic blood loss.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Polymalt — Official Regulatory Information

The eligibility profile for Polymalt, a haematinic combination product, is strictly governed by governmental regulatory classifications, defining permitted and prohibited patient populations.


Populations for whom use is contraindicated:

Contraindicated Condition Regulatory Classification
Iron Overload Syndromes (e.g., hemochromatosis, hemosiderosis) Contraindicated
Anemia Not Caused by Iron Deficiency Contraindicated
Disturbances in Iron Utilization (e.g., thalassemia, sideroblastic anemia) Contraindicated
Known Hypersensitivity to any component Contraindicated

Age and Physiological State Eligibility:

Population Group Eligibility Status (as stated in label)
Adults and Adolescents (generally ge 12 years) Allowed under standard labeled conditions
Children (le 12 years) Not recommended for some solid formulations
Pregnancy Permitted after the first thirteen weeks (second and third trimesters)
Lactation (Breastfeeding) Permitted during breastfeeding

Eligibility-Related Restrictions:

Use of Polymalt requires special consideration in patients receiving repeated blood transfusions due to the risk of iron overload. Caution is also advised for patients with severe liver and kidney diseases and in cases of anemia related to infection or malignancy, where treatment is often conditioned on addressing the primary disease first. The profile is strictly defined by the presence of iron deficiency and the absence of iron-accumulating or non-responsive disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Polymalt (Iron(III)-hydroxide Polymaltose Complex) is distinct from that of simple ferrous iron salts due to its specific chemical structure, which is designed to minimize typical iron-drug binding interactions.

Documented Interaction Profile

Product Categories and Substances Interaction Context and Practical Implication
Tetracycline Antibiotics Co-administration does not result in clinically significant absorption inhibition; no mandatory administration timing separation is required.
Antacids (e.g., Aluminum Hydroxide) Concurrent use has been found not to lead to statistically or clinically significant changes in the iron uptake of the complex.
Ascorbic Acid (Vitamin C) Co-administration may slightly increase iron absorption, but this does not lead to a reduction of the iron(III) state.

Interaction-Related Constraints

Polymalt is generally classified as having a low potential for clinically significant drug interactions. This minimal interaction profile is a result of the stable iron complex, which limits the ability of other agents to chelate or bind the iron. Therefore, official regulatory documentation typically does not impose the strict timing or separation requirements commonly necessary for simple ferrous salts when taken with medications like tetracyclines or antacids. The official interaction statements reflect the limited risk of reduced effectiveness for co-administered medicines.

Mechanism of Action

Controlled Iron Delivery for Hemoglobin Assembly

The mechanism involves the delivery of ferric iron ( Fe^3+) from the Iron(III)-hydroxide polymaltose complex (IPC). This complex provides Fe^3+ through a controlled release for uptake by the intestine and subsequent binding to the transport protein, Transferrin. This interaction delivers the essential raw substrate for the final steps of heme and hemoglobin synthesis within bone marrow precursors. This supports the increase of the blood's oxygen-carrying capacity.


B12 Cofactor Function for Red Blood Cell Maturation

The mechanism of Cyanocobalamin (Vitamin B12) involves its function as a cofactor for enzymes like Methionine Synthase, which is critical for enabling DNA synthesis in blood cell precursors. This activity ensures the proper nuclear maturation and cell division of developing red blood cells in the bone marrow. This supports the maintenance of normal erythrocyte size and function during cell division.


Synergistic Action in Coordinated Erythropoiesis

The overall mechanism involves the combined delivery of the substrate (Iron) and the relevant enzymatic cofactor ( B12). This coordinated delivery ensures that the production of properly structured erythrocytes has access to both the metallic O2-carrying substrate and the B12-dependent enzymatic machinery.

Dosage and Administration Information

How to Use Polymalt: Administration Guidelines

Polymalt is a combination haematinic preparation administered exclusively by the oral route, available in various forms, including tablets, capsules, syrup, and drops. Its usage is based on the dosing guidelines for its key active component, Iron(III)-hydroxide polymaltose complex (IPC).


Dosing and Administration

Usage Parameter Guideline Parameter
Route of Administration Oral.
Standard Adult Dose 100 mg to 200 mg elemental iron daily for manifest deficiency, or 100 mg daily for latent deficiency or prophylaxis.
Timing with Food It is recommended to take the medicine during or immediately after a meal.
Frequency Once daily, or divided into separate doses depending on the total required amount.

Procedural and Duration Rules

Standard instructions include specific conditions for proper use:

  • Preparation: Oral drops and syrups may be mixed with fruit or vegetable juices or added to bottle-feed (for infants); the slight resulting color change does not affect efficacy. Tablets may be chewed or swallowed whole.
  • Pediatric Dosing: Dosing for children and infants is highly individualized and is based on age or body weight, often using the liquid formulations.
  • Treatment Duration: Administration must be continued for at least one additional month after clinical symptoms of deficiency resolve and blood values normalize. This extended period is necessary to ensure the replenishment of the body's iron stores.
  • Special Condition: The appearance of dark-colored stools is a documented, expected observation during oral iron therapy and is not considered clinically significant.

These instructions define the quantity, timing, and duration required for the standardized use of the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Polymalt


Evidence for use in Iron Deficiency Anemia (IDA) and Latent Deficiency

Research exploring the use of the iron component in patients with Iron Deficiency Anemia (IDA) and for the potential for shifts in low iron stores, known as latent iron deficiency, was conducted. The core research includes many Randomized Controlled Trials (RCTs) and meta-analyses in which the iron complex was studied alongside other iron preparations, such as ferrous salts, or a placebo. These trials monitored physiological strain by primarily measuring changes in key blood markers, like Hemoglobin (Hb) levels, and shifts in iron stores, monitored through Serum Ferritin.

Studies report that the patterns observed in adult populations with IDA described changes in Hemoglobin levels that were generally similar to the changes measured when participants received older iron salts. What remains uncertain is the consistency of these patterns across all groups, as findings were mixed in some systematic reviews, particularly when evaluating the iron complex alongside older treatments in pregnant women and children.


Evidence for use in Combined Iron and Vitamin B12 Nutritional Deficiency

Polymalt is defined by its two key components: the iron complex and Cyanocobalamin (Vitamin B12). Research examined the process of shifts toward the normal range in markers in patients with confirmed dual deficiencies who received this combination. Clinical reports describe patterns observed in these studies where the administration of the combined nutrients was associated with changes in markers for Iron and B12 reserves.

However, evidence quality varies across studies for this combination. Comparative evidence is lacking. It is not yet clear whether the specific contribution of treating the two deficiencies simultaneously with this exact combination product has been rigorously quantified in large, comparative RCTs when evaluated against single-nutrient regimens. Therefore, the certainty remains low regarding the direct, unique contribution of the combination product over its single components.


Long-Term Studies and Follow-Up

The majority of pivotal studies that established the core evidence base for the iron component were conducted over a short-term follow-up duration, typically between 8 and 13 weeks. Research exploring changes in iron stores extended to an intermediate-term follow-up, sometimes lasting up to 8 months. Long-term effects are not fully established, meaning sustained changes in iron and B12 markers over multiple years have not been thoroughly characterized in large-scale trials.

Key Studies & References Iron(III)-hydroxide Polymaltose Complex in Iron Deficiency Anemia: A Meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Polymalt (FAQ)

Q: Is Polymalt the same as other iron supplements like ferrous sulfate?

A: Polymalt is chemically different from simple iron salts like ferrous sulfate. According to official product information, Polymalt contains the Iron(III)-hydroxide polymaltose complex (IPC), which is a stable, non-ionic macromolecular structure. Simple iron salts are ionic, whereas the IPC structure is intended to prevent the release of free iron ions in the gut.

Q: How does Polymalt claim to be gentler on the stomach compared to traditional iron supplements?

A: The IPC structure is designed to limit the release of free iron ions in the gut. This non-ionic binding of the iron is the mechanism that is believed to result in improved gastrointestinal tolerance and potentially fewer digestive issues compared to older ferrous iron salts, as indicated in regulatory documents.

Q: How long does it typically take to feel the effects of Polymalt?

A: Official clinical trial data show a rise in Hemoglobin (Hb) concentration, a key measure of red blood cell function, often within approximately 4 to 12 weeks of starting treatment. Regulatory guidelines indicate that the administration duration must continue for at least one additional month after blood values have normalized to ensure the replenishment of iron stores.

Q: Does Polymalt cause constipation more or less often than other iron medications?

A: Regulatory documents list common gastrointestinal effects like constipation, nausea, and diarrhea as uncommon or rare for the Polymalt iron complex. The clinical profile often describes a lower incidence of these adverse events for the iron complex compared to simple ferrous iron salts.

Q: Are there any specific vitamins that shouldn't be taken with Polymalt?

A: The official documentation only specifically addresses co-administration with Ascorbic Acid (Vitamin C), which may slightly increase iron absorption. If combining Polymalt with other vitamin supplements, individuals should consult their specific product's labeling or a healthcare professional for guidance.

Q: Is Polymalt suitable for use in children?

A: The eligibility profile includes children, but the product label indicates that dosing is highly individualized and based on age or body weight. Official guidelines state that some solid forms (like tablets or capsules) are not recommended for children 12 years of age or younger, and liquid formulations are often preferred for this population.

Q: Can men use Polymalt for iron deficiency, or is it mainly for women?

A: Polymalt is indicated for correcting and preventing specific nutritional deficiencies in the entire adult population. Use is not restricted by gender; the decision to use the product is solely based on a medical diagnosis of the underlying iron and/or Vitamin B12 deficiency.

Q: How long can a person safely stay on Polymalt therapy?

A: Treatment must be continued for at least one additional month after clinical symptoms and blood values have resolved and normalized to replenish the body's iron stores. The majority of pivotal studies examining the core evidence base were conducted over a short-term (8 to 13 weeks) or intermediate-term (up to 8 months) duration.

Q: What are the signs that Polymalt is starting to work for my iron deficiency?

A: The effectiveness of the medication is primarily defined by medical professionals observing changes in key blood markers. These include Hemoglobin (Hb) levels and the shift in iron stores, which are monitored through blood tests like Serum Ferritin. These laboratory changes are the primary way a healthcare professional determines the success and duration of the therapy.

Q: Can people with kidney issues take Polymalt?

A: Official regulatory documents advise that caution is necessary for patients with severe kidney diseases. Individuals with severe kidney diseases require special consideration, and use of the product should be discussed with a healthcare professional.

Q: Does Polymalt contain any common allergens like gluten or soy?

A: The product labeling states that Polymalt is contraindicated for individuals with a known hypersensitivity or allergy to any of its components. Specific details regarding common allergens like gluten or soy would be found in the full list of inactive ingredients (excipients) on the product label. This information should be verified.

Q: Are there specific food types that block the absorption of Polymalt?

A: The stable structure of the iron complex is designed to minimize its interaction with many common dietary inhibitors. Therefore, official regulatory documents do not impose the strict timing requirements often necessary with simple ferrous salts to avoid dietary absorption interference.

Q: Is it better to take Polymalt in the morning or at night?

A: Official guidelines recommend taking the medicine during or immediately after a meal. There is no specific requirement regarding the time of day, such as morning or night, as long as the medication is taken with food.

Q: What is the significance of the research on Polymalt's absorption rate?

A: Research has described the controlled release of ferric iron from the complex for uptake by the intestine, rather than the rapid release of free iron. This specific mechanism is important because it is cited as the reason for the medication's intended better gastrointestinal tolerance compared to simple iron salts.

Q: Do many people stop taking Polymalt because of side effects?

A: Official regulatory labeling classifies gastrointestinal adverse events as uncommon or rare. The product is specifically designed to improve patient tolerance and compliance by minimizing the free iron that often causes digestive issues with other oral iron supplements.

Q: Can you take iron supplements like Polymalt if you don't have a diagnosed deficiency?

A: The medication is indicated for correcting and preventing specific nutritional deficiencies. It is contraindicated in individuals with conditions of iron overload, such as hemochromatosis, and for anemias not caused by iron or B12 deficiency.

Q: What is the half-life of the iron component in Polymalt?

A: According to the official product information, the plasma half-life of the iron component following a 100 mg dose is approximately 22 hours. However, iron that is absorbed and stored in the body can persist for months.

Q: Are there different forms of Polymalt (e.g., liquid, tablet, capsule)?

A: Yes, regulatory documents indicate that Polymalt is a combination haematinic preparation available for oral use in various forms. These commonly include tablets, capsules, syrup, and drops.

Q: Why is there sometimes a metallic taste after taking iron supplements like Polymalt?

A: While the specific iron complex is designed to minimize free iron, a metallic taste may still be listed as a potential, though often uncommon, adverse event for some oral iron preparations. If this is a persistent issue, it is recommended to discuss it with a healthcare professional.

Q: What is the patient experience generally like with Polymalt therapy?

A: Clinical trial data frequently report that the medication is associated with fewer gastrointestinal side effects compared to older iron salts. This profile is intended to result in better patient tolerability and adherence to the therapy.

Q: Is it normal to feel slightly dizzy when starting a new iron supplement like Polymalt?

A: Dizziness is not listed as a common adverse event in the official regulatory labeling for Polymalt. Any unexpected symptoms should be discussed with a healthcare professional.

Q: Are there generic versions of Polymalt available?

A: The active ingredient, Iron(III)-hydroxide polymaltose complex, is identified by a unique substance code and is marketed under various brand names globally. The availability of a generic alternative depends on local regulatory registration and should be verified with a pharmacist.

Q: Does Polymalt have a lower risk of overdose compared to simple iron salts?

A: The complex's structure is designed to limit the release of free iron, which is the form that contributes to severe iron toxicity. While all iron products carry an overdose risk, this design mechanism suggests a distinct safety profile.

Q: Can I take Polymalt while fasting?

A: Official guidelines recommend taking the medicine during or immediately after a meal. Taking the medication on an empty stomach is not the preferred method of administration according to regulatory documentation.

Q: Why is the iron in Polymalt a different type than the iron found in food?

A: The iron in Polymalt is sourced from a synthetic/derived macromolecular complex called Iron(III)-hydroxide polymaltose complex. This structure is a pharmaceutical delivery system where ferric iron ( Fe^3+) is non-ionically bound to a carrier, differentiating it from iron naturally found in dietary sources.

Q: What is the bioavailability of Polymalt compared to other oral irons?

A: Meta-analyses and clinical studies report that the iron complex is effective in achieving similar Hemoglobin (Hb) levels compared to ferrous sulfate when administered at equivalent doses. This suggests that the IPC form has comparable overall clinical efficacy to older oral iron treatments.

Q: Does Polymalt contain Vitamin B12 or Folic Acid?

A: Polymalt is a combination product that contains Iron(III)-hydroxide polymaltose complex and Cyanocobalamin (Vitamin B12). The inclusion of Folic Acid is not standard across all formulations, and the specific product label should be checked.

Q: Is it necessary to have blood tests while taking Polymalt?

A: While official labeling does not mandate tests, regulatory documents state that administration must continue until blood values normalize and iron stores are replenished. This treatment goal necessitates laboratory monitoring, such as Hemoglobin and Ferritin testing, overseen by a healthcare professional.

How should Polymalt be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Polymalt

The storage and disposal of Polymalt (Iron(III)-hydroxide polymaltose complex) must adhere strictly to official regulatory instructions to maintain product stability and safety.

Requirement Category Official Labeled Instruction
Temperature & Light Store below 30 C and be protected from direct light in a cool, dark place. The product must not be frozen.
Container & Integrity Keep the medicine in its original container and original carton box until the expiry date.
Child Safety Store the medicine out of the reach and sight of children.
Disposal Disposal of unused or expired product must not be via wastewater or household waste; it must be done in accordance with local requirements (e.g., consult a pharmacist).

The regulatory profile mandates storing the medicine under controlled temperature, ensuring it is protected from light, and maintaining its packaging integrity. For disposal, instructions prohibit discarding the product into domestic waste streams, requiring compliance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Polymalt found in:

A-Z Index: